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A cell–ECM screening method to predict breast cancer metastasis† 
L. E. Barney,a E. C. Dandley,b L. E. Jansen,a N. G. Reich,c A. M. Mercuriod and 
S.  R. Peyton*a 
Breast cancer preferentially spreads to the bone, brain, liver, and lung. The clinical patterns of this tissue-
specific spread (tropism) cannot be explained by blood flow alone, yet our understanding of what 
mediates tropism to these physically and chemically diverse tissues is limited. While the micro- 
environment has been recognized as a critical factor in governing metastatic colonization, the role of     
the extracellular matrix (ECM) in mediating tropism has not been thoroughly explored. We created a 
simple biomaterial platform with systematic control over the ECM protein density and composition to 
determine if integrin binding governs how metastatic cells differentiate between secondary tissue sites. 
Instead of examining individual behaviors, we compiled large patterns of phenotypes associated with 
adhesion to and migration on these controlled ECMs. In combining this novel analysis with a simple 
biomaterial platform, we created an in vitro fingerprint that is predictive of in vivo metastasis. This   rapid 
biomaterial screen also provided information on how b1, a2, and a6 integrins might mediate metastasis in 
patients, providing insights beyond a purely genetic analysis. We propose that this approach of screening 
many cell–ECM interactions, across many different heterogeneous cell lines, is predictive of in vivo 
behavior, and is much simpler, faster, and more economical than complex 3D environments or mouse 
models. We also propose that when specifically applied toward the question of tissue tropism in breast 
cancer, it can be used to provide insight into certain integrin subunits as therapeutic   targets. 
Introduction 
Breast cancer is the most common cancer in women,  and  meta- 
stasis is responsible for 90% of all cancer deaths. The microenviron- 
ment  is  a critical  regulator  of  metastasis,1  and  in vivo studies   have 
provided insight into many microenvironment-mediated 
mechanisms.2–6 However, these studies lack features of human 
physiology, contain uncontrolled variables, and are often not 
comparable across different mouse models. Thus, it is difficult   
to parse the varying contributions of each factor, limiting the 
broad applicability of these results. In contrast, in vitro models 
can be either oversimplified,7 or highly complex, expensive, low-
throughput, and limited to highly specialized laboratories.8 
Because metastasis remains both largely incurable and poorly 
understood, there is a need for quick, cost-efficient  in  vitro 
model systems with enough complexity to recapitulate certain 
aspects of in vivo biology, while maintaining affordability and 
efficiency. 
Two-dimensional in vitro disease models are appropriately 
low cost and simple, however, it is now generally appreciated 
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Insight, innovation, integration 
We developed a high-throughput method to rapidly screen cell adhesion, motility, and growth factor responses on biomaterial surfaces. This approa ch is 
analogous to systems biology, relying on cell phenotypes in lieu of genetics. We used this technique to reveal patterns of phenotypes associated with breast 
cancer metastasis to possible tissue sites (bone, brain, lung). By comparing the phenotypic patterns between cell lines that metastasize to only one tissue site 
with heterogeneous cell lines, we provide the first method to connect in vitro phenotype to in vivo fate. This method is successful without genetic analysis, yet it 
also predicts outcomes related to integrin gene expression, potentially identifying new targets for tissue-specific metastasis.  
 
 
 
that two-dimensional cell behaviors are usually not conserved   
in a three-dimensional context. One recent example of this is 
work by Meyer et al., which showed that only two-dimensional 
growth-factor induced membrane protrusion, but not any other 
measured 2D motility parameter, accurately predicts 3D moti- 
lity.9 This suggests that individual two-dimensional measure- 
ments will also not be predictive of even more complex in vivo 
cell phenotypes. We suggest that a better approach may be to 
avoid measurements of single, likely non-predictive  metrics,  
and instead, measure patterns of many phenotypes across 
several conditions  and  several cell  sources.10 
Breast cancer metastasis is a clear candidate for this type of 
approach because of its striking, yet unexplained, clinical 
patterns of metastatic spread (tropism) to  the  bone,  brain,  
liver, and lung, but not to tissues such  as  the  skin,  heart,  
uterus, or spleen.11,12 This tropism is hypothesized to depend 
upon an unknown relationship between metastatic cells (the 
seeds) and hospitable microenvironments (the soils).12 Because 
the tissues often colonized by breast cancer cells each have a 
distinct ECM, we posit that integrin binding to the ECM is one 
feature that plays a critical role in the early stages of tissue- 
specific colonization and fate of extravasated cancer cells. It is 
known that secondary site colonization requires activation of 
integrin-mediated signaling,10,13–16 and several individual 
integrins  have  been  implicated  in  breast  cancer  metastasis   
in vivo.17–20  However,  this  research  is  limited  to  metastasis  at 
a single tissue site, or to the effect of a single integrin, which is 
not representative of the variety of cell–matrix interactions 
simultaneously occurring in vivo during cell adhesion to a 
secondary  tissue  site post-extravasation. 
To this end, we created a novel biomaterial platform com- 
prised of complex ECMs that can present any combination of full-
length proteins with high fidelity, reproducibility, and is 
permanent during the cell culture period. We used this bio- 
material to quantify how different metastatic breast cancer cell 
lines differentiate between secondary sites via integrin binding. 
We compiled sixty-six distinct cell phenotypes associated with 
cell adhesion and motility, both with and without epidermal 
growth factor (EGF)  stimulation. By collating all the responses  
to each biomaterial ECM surface together, we created a pheno- 
typic  fingerprint  of  bone,  brain,  and  lung  metastasis,  which  is 
tropic cell subpopulations, as well as predictive of the in vivo 
metastasis of several other more heterogeneous cell lines, 
thereby predicting in vivo fate with a quick in vitro screen. Taken 
together, we propose this comprehensive analysis of cell–matrix 
interactions as a tool to predict in vivo fate, as well as understand 
the roles of integrins in tropism, thus providing insight toward 
integrins as druggable targets for metastatic disease. 
Results 
Rapid biomaterial screening of cell–ECM interactions 
The ECMs present in secondary tissues often recipient of breast 
cancer colonization are each strikingly complex and distinct,21 
suggesting that cell–matrix interactions play a role in mediating 
metastasis. Our goal here was to create a simple in vitro 
biomaterial system to investigate  the  role  of  integrin  binding 
in breast cancer tropism. These biomaterial surfaces are glass 
coverslips, modified via straightforward silane chemistry. They 
present covalently coupled ECM proteins, and they remain  
stable throughout the cell culture period (at least 72  hours). 
This method can be used to couple any combination of full- 
length proteins or peptides of interest, providing control over 
cell–matrix interactions in a highly robust (Fig. S1, ESI†), 
scalable, and facile process. It is particularly well suited to 
observe integrin-mediated phenotypes of adherent cell lines,  
and   allows   for   functional   investigation   of   real-time binding 
to the  ECM. 
We used this approach to create three ECM microenviron- 
ments containing combinations of ECM  proteins  inspired  by  
the biochemical cues found at the in vivo  tissues  to  which  
breast cancer commonly spreads (Table 1). ECM at these tissues 
has significant patient-to-patient variability,21 and can be remodelled 
by both tumor and stromal cells over time.5,6 Our approach was 
to determine if integrin binding alone, at early time points 
(directly after extravasation), was sufficient to direct or predict 
tissue-specific spread. Therefore, we created three biomaterial 
surfaces containing combinations of ECM proteins that isolate 
distinct integrin heterodimers, independently of the in vivo 
heterogeneity, inspired by the ECM protein content of healthy 
tissues  at  these sites.6,22–26 both  capable  of  distinguishing  between   genetically related 
Table 1     Composition  of  tissue-inspired  biomaterial ECMs 
ECM  1 (bone) ECM  2 (brain) ECM  3 (lung) 
In  vivo  ECM density High Low Moderate 
Fibronectin6 
Collagens laminins elastin tenascin C proteoglycans26 
In vivo ECM proteins Collagen I 
Fibronectin22 
Osteopontin23 
5 mg cm-2 
99%  collagen I 
1% osteopontin 
Laminin fibronectin collagen IV tenascins 
proteoglycans24 
Hyaluronic acid25 
1 mg cm-2 
50% fibronectin 
25% vitronectin 
20% tenascin C 
5% laminin 
2 mg cm-2 
33% laminin 
33%  collagen IV 
15%  collagen I 
15% fibronectin 
4% tenascin C 
In  vitro  ECM density 
In vitro ECM proteins 
 
 
 
 
Fig. 1 Biomaterial platform for integrin-mediated phenotyping. (a) Breast cancer cell lines with their known in vivo metastatic tropisms.2–4,28–33 (b) 
Three distinct ECM microenvironments regulate integrin binding. (c) Adhesion and motility phenotypes of the MDA-MB-231 cell line. Black: ECM 1; blue: 
ECM 2; green: ECM  3. 
As a first attempt to capture the heterogeneity of breast 
cancer, we screened phenotypes associated with adhesion and 
motility across a large panel of human cell lines that span the 
clinical subtypes27 and metastatic specificity to the bone, brain, 
and lung sites2–4,28–33 (Fig. 1a). We first  measured  spreading  
and polarization of cells during initial adhesion to the ECMs, 
quantifying time-dependent cell area, spreading rate, and 
polarization of the population (Fig. 1c top and Fig. S2a–c, ESI†). 
Next, we observed long-term motility, and quantified cell 
migration speed, displacement, and chemotactic index (ratio of 
displacement to path length, quantifies migration straightness) 
(Fig. 1c bottom, Fig. S2d–f, ESI†). Altogether, 550 individual cell 
observations were made per cell line on average (Fig.  1c and  
Fig. S2, ESI†). In combination with an ELISA characterization of 
the protein coupling (Fig. S1, ESI†), these measurements validate 
the biomaterial platform as being able to elicit differential cell 
line responses via integrin binding  alone  (Fig.  S2, ESI†). 
We immediately noticed that for each different measure- 
ment we took, the tropic cell lines were sensitive to the ECMs in 
some cases, while insensitive in others. As an example, when 
we quantified cell speed, the bone and brain tropic cell lines 
had very different cell speeds on each ECM surface, whereas the 
lung tropic cells had similar cell speeds on all three ECMs. To 
quantifiably demonstrate this, we applied a statistical tool 
called the coefficient of variation (CoV) to each set of measure- 
ments for a given cell line. This measurement quantifies 
dispersion of a data set, and is computed by dividing the 
standard deviation of a set of measurements by their mean.  
In its application here, higher CoV values identify adhesion or 
motility measurements where a cell line is highly sensitive to 
the different ECM surfaces (i.e., the relative standard deviation 
of the measurements across each ECM is at least 10%). Because 
these cell lines were created to exhibit strong in vivo metastasis 
to one site, we first wanted to validate that this in vivo selectivity 
was reflected in the in vitro cell–ECM screen. This CoV analysis 
showed that each of the tropic cell subpopulations was signifi- 
cantly more sensitive to the ECMs than the parental cell line in 
each of the adhesion and motility phenotypes we quantified 
(Fig. S4a, ESI†), validating this approach. 
Given that tropic  cell  lines  have  heightened  sensitivity 
to growth factors,34 we then quantified the change in each 
adhesion and motility metric in response to EGF stimulation, 
and found that the patterns of adhesion and motility across the 
ECMs under normal and EGF-stimulated conditions varied 
significantly between the tropic cell lines (Fig. S3, ESI†). The 
effect of EGF stimulation was especially striking in the tropic 
cell adhesion. EGF slowed spreading and polarization of the 
bone tropic cell line, while it increased the spreading rate of the 
brain and lung tropic cell lines in an ECM-dependent fashion 
(Fig.  S3a–f,  ESI†).  Growth  factor  sequestration  and growth 
Phenotypic screen predicts tissue tropism in  vivo 
We hypothesized that an in vitro analysis of integrin-mediated 
phenotypes would be capable of differentiating cell lines with 
different tropisms in vivo, reflecting the functional binding 
interactions required for successful metastatic outgrowth. We 
began by phenotyping three highly tropic subpopulations of the 
MDA-MB-231 parental cell line, which were selected from in vivo 
metastases by Massague´ and colleagues.2–4 These geneti- cally 
distinct MDA-MB-231 subpopulations each display strong 
tropism to either the bone (‘‘bone tropic’’),2 brain (‘‘brain 
tropic’’),4  or lung (‘‘lung tropic’’)3  in mice, and have been used    
to identify genetic determinants of tissue-specific metastasis.  
We found that these tissue-specific cell lines each responded to 
the ECMs in unique ways (Fig. S3, ESI†). 
 
 
Fig. 2 Phenotypic fingerprint predicts bone, brain, and lung metastasis. Development of phenotypic fingerprints of bone, brain, and lung tropism from 
patterns of integrin-mediated behavior. The (a) CoV, (b) EGF response, and (c) measurement ordering features were measured for each tropic cell line to 
create a fingerprint. (d, e) Phenotypic fingerprints of tropic behavior (rows), with unique identifiers distinguished in dark colors. (d) Coefficient of variation 
for  both  the  normal  and  EGF-stimulated  conditions.  Blue:  high  CoV  (40.1);  grey:  low  CoV  (o0.1).  (e)  EGF  response  on  each  ECM.  Red:  increase 
(fold change 4 1.15); grey: no change; green: decrease (fold change o 0.85). Pairwise ordering is provided in Fig. S4b (ESI†). Abbreviations: 1: ECM 1; 2: 
ECM 2; 3: ECM 3; SR: spreading rate; A: area; P: polarization; S: speed; D: displacement; CI: chemotactic index. (f) Fingerprint of heterogeneous cell lines 
overlaid onto tropic fingerprints allows for quantification of similarity to each tropic subpopulation. Colored boxes in overlaid cell lines identify features 
shared with each tropic cell line. Black: bone tropic, red: brain tropic, blue: lung tropic. (g) In vitro tropism of the MDA-MB-231, SUM1315 MO2, BT549, 
MDA-MB-468, HCC 1954, MDA-MB-361, SkBr3, and MCF7 cell lines. Black: bone tropic, red: brain tropic, blue: lung tropic. Bars represent the percentile 
of the null distribution where each heterogeneous cell line lies, with error bars displaying the range of the respective percentile. High percentiles indicate 
cell lines that are highly phenotypically tropic to a tissue site. Statistics shown above bars indicate that the cell line is significantly higher or lower than the 
null distribution for the indicated tropism. Top labels: known in vivo tropism. Bottom labels: clinical subtype   designation. 
factor   signalling   both   depend  on   the  composition   of the All the adhesion and motility measurements were organized 
across three separate classes of observable responses to the 
ECMs (coefficient of variation, response to EGF, and pairwise 
ordering  across  ECMs,  Fig. 2a–c). 
As the first feature of these collective tropic phenotypes, 
measurements in which the cell line was either highly sensitive 
or insensitive to changes in the ECM were identified (Fig. 2a). 
ECM,35,36 which, in addition to the  differences in the     tropic 
subpopulations, is likely one reason for the differences in EGF 
responses. 
With this collection of measurements, we sought to identify 
all the phenotypes unique to cells metastasizing to the bone, 
brain, or lung by compiling them en masse into a heat map. 
 
 
For example, the lung tropic line has a high spreading rate CoV, 
whereas the brain tropic cell line has a low chemotactic index 
CoV under EGF stimulation (Fig. 2a). We then quantified 
whether each phenotype measured increased, decreased, or 
remained unchanged in response to EGF stimulation on each 
of the three ECMs (Fig. 2b). As examples, the lung tropic cells 
increased their displacement with EGF stimulation, the bone 
tropic cell line spreading area was unchanged, and the brain 
tropic cell speed decreased upon EGF stimulation (Fig. 2b). 
Finally, a pairwise statistical test was used to compare each 
phenotype measured across each of the ECM surfaces, resulting 
in an ‘‘ECM ordering’’ (Fig. 2c). As an example, the lung tropic 
cell line has the statistically highest spreading rate on ECM 3, 
followed by ECM 1, and is lowest on ECM 2 (Fig. 2c). In 
contrast, the chemotactic index of the brain tropic cell line 
was statistically equivalent on all ECMs. 
We computed each of these features for all phenotypes and 
compiled this into a heat map, creating a row for each tropic    
cell line (Fig. 2d, e and Fig. S4b, ESI†). The color of each box 
identifies the value of the phenotype for the respective cell line. 
For   the   CoV   measurement,   highly   sensitive    measurements 
(CoV 4 0.1) are identified with a blue box, while insensitive 
measurements (CoV o 0.1) are identified with a grey box 
(Fig. 2d). In Fig. 2e, EGF changes are determined via fold 
change from the normal measurement. An increase (fold 
change 4 1.15) is red, a decrease (fold change o 0.85) is green, 
and no change (0.85 o fold change o 1.15) is grey (Fig. 2e).    In 
Fig. S4b (ESI†), for each pairwise comparison, a blue box indicates 
that the first measurement is greater than the second, a grey box 
indicates that they are equal, and a red box indicates that the  
second measurement is greater than the first. Altogether, greater 
than 1000 individual cell observations per tropic cell line were 
quantified and compiled together to create sixty-six features of 
integrin-mediated phenotypes for each tropic cell subpopulation 
(Fig.  2d,  e and  Fig.  S4b,  ESI,† rows). 
Looking down each column in Fig. 2d, e and Fig. S4b (ESI†),  
we then identified behaviors that were specific to only one of the 
three tropic cell lines. These instances are identified by a dark 
shaded box of the appropriate color. Looking across each row, 
thirteen measured phenotypes are unique to bone tropism, a 
separate thirteen features are unique to lung tropism, and fifteen 
to brain tropism (Fig. 2d, e and Fig. S4b, ESI†). Although no 
singular adhesion or motility-associated phenotype was predic- 
tive of breast cancer tropism (not shown), this collective analysis 
of many cell responses to ECMs combined to create phenotypic 
fingerprints of bone, brain, and lung metastasis (Fig. 2d, e and  
Fig.  S4b, ESI†). 
We repeated all these measurements using more hetero- 
geneous cell lines with  known,  literature-reported  metastasis 
in vivo (Fig. 1a), and overlaid each cell line’s  pattern  of 
behaviors onto the three fingerprints of tissue-specific meta- 
stasis we created (Fig. 2f). The measurements  from  each  cell 
line can be compared to the tissue-specific fingerprints gen- 
erated from the tropic cell lines, resulting in a  fractional 
similarity value that represents the amount of unique pheno- 
typic   features   shared   with   the   cell   lines   that    specifically 
metastasize to either the bone, brain, or lung (Fig. S5a, ESI†).     
As a control, a null distribution of 10 000  cell  lines  with  
random phenotypes was generated in silico to represent ‘‘ran- 
dom metastasis’’ (Fig. S5a–d, ESI†).  We  determined  how  
similar the patterns were between each of the heterogeneous  
cell lines and the  bone,  brain,  and  lung  tropic  fingerprints  
(Fig. S5a, ESI†), and represented this as a percentile of the 
respective  null  distribution  (Fig.  2g). 
With this in vitro method, we predicted the in vivo metastasis 
of seven out of the eight heterogeneous cell lines tested. First, 
the SUM1315 MO2 cell line, which metastasizes highly to 
bone,37 most highly matches the bone fingerprint and is clearly 
anti-brain and anti-lung tropic. Both the MDA-MB-46833 and 
BT54928 cell lines metastasize to the lung in vivo, and are clearly 
lung tropic by our fingerprint. The HER2+ cell line HCC 1954 is 
lung metastatic32 and phenotypically lung tropic. The HER2+ 
MDA-MB-361 cell line was derived from a brain metastasis, 
metastasizes to the brain in mice,38 and is comparatively brain 
tropic by our fingerprint. The parental MDA-MB-231 is sponta- 
neously metastatic to many sites upon orthotopic implantation 
into the mammary fat pad39 and intracardiac injection,4,40 and 
metastasizes to the bone more than to the brain or lung 
through the latter technique.40 Our fingerprint identified this 
cell line as highly bone tropic (0.62 fractional similarity, 90th 
percentile of the randomly generated bone tropism null dis- 
tribution), significantly greater than the similarity to the brain 
and lung fingerprints, reflecting this feature of in vivo behavior 
(Fig. 2g and Fig. S5a, ESI†). We focused on this particular aspect 
of MDA-MB-231 behavior, as this is the parental cell line from 
which the bone, brain, and lung tropic cell lines were derived 
by  Massague´.  As  a  non-tropic  control,  the  MCF7  cells  are  only 
moderately metastatic, and not tissue-specific,29,30 and were 
not tropic to any one tissue based on our fingerprint. Finally, 
the HER2+ SkBr3 cells were identified as brain tropic in our 
approach, but they are not highly tumorigenic or metastatic to 
the brain or other sites in vivo.31 HER2-overexpressing tumors 
often spread to the brain in humans,11 which may explain the 
prediction we obtained. However, we would argue that this 
example shows that this approach, although highly predictive, 
is not 100% accurate, and is only a predictor of tissue selectivity, 
not metastatic capability. 
When looking more closely, we discovered that the unique 
features making up each fingerprint are primarily comprised of 
differential responses to EGF stimulation. In fact, all of the 
features in the bone tropic fingerprint are related to EGF 
stimulation, 80% for the brain fingerprint, and 62% for the 
lung fingerprint. Concurrently, we found that the cell lines with 
higher EGFR mRNA expression displayed stronger matching to 
just one of the tropic fingerprints than the cell lines with lower 
EGFR expression (Fig. 2g and Fig. S5e, ESI†). Using published 
proteomic data,41 we discovered a strong correlation between 
basal  EGFR  expression  in  our  cell  lines  and  the  CoV  of  the  
in vitro tropism (Fig. S5f, ESI†), confirming this  qualitative  
trend. Although outside the scope of this study, we speculate  
that   a   more   exhaustive   screen   of   additional   growth factor 
responses, or across different ECM protein combinations, could 
 
lend even more specificity for this fingerprinting approach, 
potentially resolving the inconsistency we observed in the SkBr3 
cell line. 
In sum, we compiled sixty-six features of integrin-mediated 
phenotypes observed in bone, brain, and lung tropic cell lines 
into an in vitro fingerprint, which predicted the in vivo meta- 
stasis of other more heterogeneous cell lines. We  stress  that 
this result was impossible to achieve using any single adhesion  
or motility measurement, and  instead  required  quantification 
of patterns of behavior. Because only some singular features of 
two-dimensional cell behavior can predict responses in a more 
realistic  three-dimensional  environment,9   this   requirement 
was perhaps not surprising. The divergence between two and 
three-dimensional phenotypes necessitated this new method of 
analysis to accurately connect measurements made in a two- 
dimensional  context  to  in  vivo outcomes. 
caused an increase in ECM sensitivity in these cells. Specifi- 
cally, the SkBr3 cells migrated faster and farther on the 
collagen-rich ECM 1 (Fig. 3c and d, arrows) in the presence of 
both of these function-affecting antibodies. Looking more 
closely at videos of the cell behaviors, we determined that the 
increase in motility was caused by complete detachment of 
individual SkBr3 cells, which would then re-adhere at different 
locations, essentially hopping along the surface of the bioma- 
terial (Fig. 3e, f and Fig. S6a, Movie S1, ESI†). This behavior 
resulted in a small population of cells that had abnormally 
fast migration speeds and long displacements (Fig. 3e, f and 
Fig. S6a, ESI†). This phenotype was observed most often on 
ECM 1 in the presence of the b1 and a2 integrin antibodies, and 
rarely in the three other conditions (Fig. S6b, ESI†). This was 
never observed  in the  MDA-MB-231 cells. 
This behavior did not resemble traditional adherent cell 
motility, and we suspected that these weakly-to-non adherent 
cells might be highly invasive in a 3D context, perhaps resem- 
bling an amoeboid-type motility.44 When these same b1 and a2 
integrin antibodies were administered to SkBr3 cells that were 
seeded onto ECM 1 overlaid with a 3D collagen gel, we  observed 
increased upward 3D invasion by three to four fold compared to 
the control (Fig. 3g and Fig. S6c, ESI†). The SkBr3 cell line has 
lower integrin protein expression of each of these integrin 
subunits in comparison to the MDA-MB-231 cell line,45,46 which  
is potentially responsible for the detachment and invasion 
phenotypes. However, there were no differences in b1 integrin 
mRNA expression (Fig. S7a, ESI†), suggesting that a proteomic, 
but not a genomic analysis could have predicted this result. We 
propose that the motility and invasion of some cancer cell lines 
can actually be increased when targeting integrins,47 potentially 
limiting the efficacy of this class of therapeutics  in  some 
patients. The  striking  differences in  antibody responses of    the 
triple negative MDA-MB-231 and HER2+ SkBr3 cell lines high- 
light the heterogeneity in response to integrin therapeutics 
observed across different breast cancer clinical subtypes, poten- 
tially explaining the limited efficacy of these drugs thus far. 
Targeting integrin binding on in vitro ECMs reveals the need 
for subtype-specific analysis 
Integrins have been explored as cancer therapeutics in pre- 
clinical and clinical trials, but many of these drugs have only 
shown limited success.42 We hypothesized that this lack of 
clinical efficacy may be in part from differential responses 
across the heterogeneity of breast cancer subtypes. Because 
we are controlling for integrin-binding on our ECM protein- 
coupled surfaces, our predictive phenotyping platform provides 
a unique opportunity to investigate integrins as therapeutic 
targets for metastatic disease. We focused on triple negative 
and HER2+ cancer, which both have particularly poor pro- 
gnosis. As proof of concept, we chose MDA-MB-231 as a 
representative triple negative cell line, and used the SkBr3s to 
examine HER2+ breast cancer. We focused on integrin subunits 
with various affinities to the proteins on each of our ECMs: b1, 
which is involved in  binding  to  many  proteins  across  all  the 
in vitro ECMs; a2, which binds primarily to collagens but also to 
laminin (collagen is present on ECMs 1 and 3;  laminin  is  
present on ECMs 2 and 3); and a6, which specifically binds 
laminin (present on ECMs 2 and     3).43 
We performed the same adhesion and motility experiments 
from Fig. 1c in the presence of function-affecting antibodies to 
these three integrins. Targeting the function of each integrin 
reduced both cell adhesion and migration of the MDA-MB-231 
cell line on the three ECMs. When cell adhesion measurements 
were plotted against cell migration measurements for each 
antibody of interest (as well as without antibody and with 
EGF stimulation), the responses clustered together (Fig. 3a 
and b). This revealed that the MDA-MB-231 cells were overall 
more sensitive to the antibody treatments and EGF stimulation 
than they were to the three ECMs. Each antibody had a different 
potency, resulting in a strong correlation between two measure- 
ments of cell adhesion (spreading rate and maximum area) and 
motility (migration speed and displacement, Spearman correla- 
tions and p-values shown in Fig. 3a and  b). 
This same clustering of responses around each ECM was not 
observed in the HER2+ SkBr3 cell line. Most surprisingly, 
treatment   with   the   b1    and   a2    integrin   antibodies   actually 
Integrin binding and expression dictates  tropism 
The b1, a2, and a6 integrin subunits each have a reported role in 
cancer: high expression of both b1 (ref. 48) and a6 (ref. 49) 
integrins drives tumorigenicity and metastasis, while a2 integ- 
rin is a tumor suppressor.50 Although all three integrins appear 
important in overall patient prognosis, none have been directly 
connected with tissue-specific metastasis. Given the results in 
Fig. 2, where tropic cells shared similar integrin-mediated 
phenotypes,  and  Fig. 3, where  the  triple negative MDA-MB-231 
and HER2+ SkBr3 cell lines had divergent responses to integrin 
targeting, we hypothesized that targeting b1, a2, and a6 integrins 
could shift the observed in vitro tropism of these cell lines. 
We compiled the adhesion and motility measurements for the 
MDA-MB-231 and SkBr3 cell lines that were performed in the 
presence of integrin antibodies  into  our  predictive  fingerprint. 
This treatment with integrin antibodies, which lowers the binding 
ability with these integrin subunits, shifted the tropism  predic-  
tions  of  both  cell  lines  (Fig.  4a and  b).  In the  MDA-MB-231 cells, 
 
Fig. 3 Correlations between adhesion and migration responses identify potent integrin antibodies in vitro. Pairwise comparisons between adhesion and 
migration measurements in the (a, b) MDA-MB-231 and (c, d) SkBr3 cell lines across normal, EGF-stimulated, and integrin antibody conditions. Arrows 
highlight conditions where integrin antibodies increased migration metrics. Spearman correlations are indicated on each plot with two-tailed p-values. 
Circle: ECM 1; square: ECM 2; triangle: ECM 3; black: normal; green: EGF; blue: anti-b1 integrin; red: anti-a2 integrin; orange: anti-a6 integrin. (e, f) SkBr3 
migration mechanisms are displayed via 10 random cell paths under (e) normal and (f) anti-b1 conditions. Red paths identify cells detaching and adhering 
elsewhere on the surface. Inset: representative images of cell morphology. Scale bar is 25 mm. (g) Individual cells that invaded into an overlaid 3D collagen 
gel from the ECM 1 surface after 48 hours. Bar indicates mean distance invaded of all invading cells. Inset: schematic of cells invading upward from the 
ECM surface into an overlaid  gel. 
treatment with any of the integrin antibodies shifted the tropism 
from bone to brain (Fig. 4a). In other words, blocking binding via 
b1, a2, or a6 integrins made the MDA-MB-231 cells less similar to 
the bone tropic fingerprint, and instead, they more resembled the 
brain tropic cell subpopulation (compare the tropism category 
containing the highest black bar with the tropism category 
containing the highest colored bars for each integrin). The SkBr3 
cells shifted from brain to bone tropic upon b1 integrin inhibition, 
they became equally brain and lung tropic when a2 integrin  was 
blocked, and a6 integrin targeting  had  no effect  (Fig.  4b).  Just  as 
we found in Fig. 3, the MDA-MB-231 cell line was far less sensitive 
to differences in ECM during  integrin  targeting  than  the  SkBr3  
cell line. Interestingly, the only response that was shared between 
the  MDA-MB-231  and  SkBr3  cell  lines  was  the  ‘‘null  effect’’      of 
targeting  a2  and  a6  integrins  on  lung  tropism.  Overall,    these 
results   suggest   that  targeting   any  one   of   these   integrins   may 
effectively prevent bone metastasis in the triple negative cell line, 
while b1 integrin may be an efficacious therapeutic  target  to 
prevent brain and lung (but not  bone)  metastasis  in  the  HER2+ 
cell  line. 
For this approach to have significant impact, it must be 
compared with clinical patient outcomes. We analyzed gene 
expression data from 630 breast cancer patients with known 
metastatic outcomes (combined from GSE 2034, GSE 2603, GSE 
5327, GSE 12276; includes 214 bone metastases, 35 brain 
metastases, 101 lung metastases). We first determined whether 
expression of these integrin genes was associated with tissue- 
specific metastasis in the clinic (Fig. 4c–e),  and then     compared 
 
 
Fig. 4 Integrin binding and gene expression predict breast cancer metastasis. Integrin antibodies shift tropic fingerprinting of (a) MDA-MB-231 and (b) 
SkBr3 cell lines. Compare the tropism containing the highest black bar (normal) with the category containing the highest value for each colored bar (blue: 
b1, red: a2, orange: a6 integrin). (c–e) Magnitude of integrin gene expression dictates (c) bone, (d) brain, and (e) lung metastasis clinically (analysis of GSE 
2034, GSE 2603, GSE 5327, GSE 12276). (f) Left, effect of b1, a2, and a6 integrin gene expression on clinical metastasis in all patients, only triple negative 
patients, and only HER2+ patients. Right, effect of b1, a2, and a6 integrin antibodies on tropic fingerprint in the MDA-MB-231 (triple negative) and   SkBr3 
(HER2+) cell lines. Red: high expression or binding predicts for increased metastasis; blue: low expression or binding predicts for increased metastasis; 
white: no effect. (g) Heat map displaying integrin genes that significantly predict for tissue-specific metastasis in patients. Blue: low expression of the 
gene predicts for increased risk of metastasis; red: high expression of the gene predicts for increased risk of metastasis; white: no effect on metastasis. 
Asterisks indicate statistically significant relationships, but other clearly visible trends are included for completeness. Abbreviations: Bo: bone metastasis; 
Br: brain metastasis; Lu: lung metastasis. 
using published annotations,4,51 and survival  analysis  is 
repeated in these smaller, specific patient populations, the 
subtype-specific trends in tropism match the behavior of 
corresponding the cell line we examined (Fig. 4f). We want to 
stress that this latter result was only one of two shared out- 
comes we found between the triple negative and HER2+ cell 
lines, highlighting  the need for individual analysis of subtypes,  
as  demonstrated  in  Fig. 3. 
Interestingly, when this clinical analysis is expanded to 
examine all integrin subunits, many are associated with meta- 
stasis to the brain, bone, or lung, but these same genes are not 
conserved   within   the   triple   negative   and   HER2+   subtypes 
this with the results predicted from our in vitro fingerprinting 
approach when targeting integrin binding (Fig. 4a and b). As 
one example, the gene expression data sets revealed that low a2 
integrin expression in the primary tumor correlates with higher 
rates of brain metastasis, and, similarly, decreasing a2 integrin 
binding significantly increased the MDA-MB-231 brain tropic 
phenotype in vitro (compare Fig. 4a, increase in brain tropism 
from black to red, with Fig. 4d, increased risk of brain meta- 
stasis from black to red). As another example, a6 integrin has 
no effect on lung metastasis, in both clinical patient outcomes 
and the tropism of both cell lines (Fig. 4a and b). In this case, 
when these same patients are classified into clinical  subtypes 
 
 
(Fig. 4g and Fig. S7b, ESI†). Strong examples are a1, a3, and   b2 
integrins, where altered expression of these genes is correlated 
with tropism to a specific tissue across breast cancer broadly, 
but they are not correlated with tropism within these two 
subtypes. Instead, different integrin subunit genes are corre- 
lated  with  tissue-specific  metastasis  within  each  of  these sub- 
types. As two examples, low a8  integrin expression is   correlated 
with bone metastasis in the HER2+ subtype, and high b1 
integrin expression is correlated with lung metastasis in the 
triple negative subtype. 
When we compared our in vitro phenotyping approach to this 
existing gene data set, we found that our in  vitro  tropism  
responses imperfectly correlated with  these  genetic  indicators. 
High b1 expression is associated with poor prognosis,
48  and in    our 
work,  targeting b1 integrin makes the MDA-MB-231 cell line    much 
less bone tropic, matching this result (Fig. 4a). However, the SkBr3 
cell line significantly increased in bone tropism upon targeting b1 
integrin, (Fig. 4b), and our clinical analysis surprisingly  showed  
that the magnitude of b1 integrin gene expression is not predictive  
of bone metastasis in patients (Fig. 4c). However, the divergent 
responses of the two candidate cell lines, from different clinical 
subtypes, combine to match the clinical pattern. Although our b1 
integrin targeting results were not predictive of these clinical 
outcomes, we emphasize that this highlights the divergence 
expected between a genetic-focused approach  and  a  protein- 
based,  functional  approach,  as  we  have  taken here. 
In sum, we have used a simple integrin-mediated pheno- 
typing approach to predict breast cancer metastasis in a large 
panel of cell lines, and we implicate b1, a2, and  a6  integrin  
binding in tissue-specific spread distinctly across several dis- 
ease subtypes, a phenomenon that is prevalent across many 
integrin gene-tissue combinations in clinical patient popula- 
tions  (Fig.  4g  and  Fig.  S7b,  ESI†).  Importantly,  our      integrin 
targeting results provide many insights not apparent in gene 
expression data, highlighting the need for functional, protein- 
centric screens of cell behaviors. We emphasize the utility of this 
phenotyping approach as quick, bench-top screening tool that 
can be used to predict in vivo outcomes. Here, we have illustrated 
this functionality by predicting metastatic outcomes and identi- 
fying biomarkers potentially overlooked when analyzing gene 
data sets  from heterogeneous  clinical  patient populations. 
either used end-point analyses or have included multiple con- 
voluted microenvironmental factors. The biomaterial platform 
we designed overcomes these limitations by mimicking some of 
the biochemical complexity present in in vivo ECMs, while 
limiting microenvironmental cues to only those ECM proteins 
presented by the system, with growth factors supplemented as 
desired. This can then be used for observing differences in 
adhesion and motility resulting from differential  binding  to 
these  multi-protein ECMs. 
We propose this system as a potential bridge between the 
overwhelming complexity of in  vivo  observations  and  simple  
in vitro cell biology, without the need for expensive or lab- 
specific 3D models. The first challenge we noted was that 
genomics is the increasingly popular approach for identifying 
cancer biomarkers due to its ease and increasingly low cost, 
facilitating large-scale patient-specific analysis. However, gene 
expression does not necessarily correlate with protein expression 
or function. Therefore, we attempted to connect gene-centric 
patient data with a protein-centric cell screening approach. 
Breast cancer was a suitably complex target to study, as it is a 
notoriously heterogeneous disease.11 This heterogeneity may be 
why integrins were not consistently strong genetic biomarkers 
across large, diverse patient populations (Fig. 4). Our protein- 
centered approach mirrored this inconsistency between the 
SkBr3 and MDA-MB-231 cell lines (Fig. 3 and 4), and we 
quantified significant differences in cell adhesion and motility 
between the three MDA-MB-231 tropic subpopulations (Fig. S3, 
ESI†), which have minimal differences in integrin gene expres- 
sion (Fig. S7a and c, ESI†).2–4 
The immediate conclusion is that differences in gene expres- 
sion of integrin subunits alone is not sufficient to mediate 
metastasis to different tissues. This remains an open question, 
as gene expression of several integrins was strongly correlated 
with tropic metastasis in patients (Fig. 4g), but most of these 
integrins have not yet been functionally examined in vivo. For 
those that have, the in vivo reports we found did not match the 
clinical correlations in our analysis of the gene data sets.    For 
example,  a3b1   integrin  binding   is  known   to  mediate   lung 
mice.18,19 metastasis  in  rats and However,  high  a3  integrin 
gene expression showed only a non-significant correlation    with 
lung metastasis, and only when we isolated the analysis to 
triple negative patients. Across all subtypes of patients, high a3 
integrin gene expression actually more highly correlated with 
bone metastasis (Fig. 4g). As another example, avb3 integrin has 
been linked to bone metastasis in rats,17 however, b3 integrin 
gene expression in these data sets does not predict for bone 
metastasis, and av integrin gene expression is only more 
strongly associated with bone metastasis in the triple negative 
and HER2+ subtypes than across all patients (Fig. 4g). It is 
important to note that clinical tumor samples contain stroma, 
are often contaminated with immune cells, fibroblasts, and 
epithelial cells,55 and even the best dissection techniques only 
produce tumor contents near 70%,3 which could skew genetic 
analysis. We stress that based on this conflict between our data 
and the genetic analysis we performed, alongside obvious 
conflicts between these gene data sets and literature  reports, 
Discussion 
Extracellular matrix (ECM) properties, such as tissue stiffness,7 
local growth factors,52 stromal cells,6,53 and ECM  proteins,5,10,54 
can each individually promote metastasis. However, we are only 
beginning to understand the role of each of these properties in 
tissue-specific metastatic colonization.5,6,52,54 To truly understand 
the microenvironmental factors that mediate metastasis, each 
factor must be systematically isolated from other cues, and 
investigated functionally in a controlled system that closely repre- 
sents the in vivo microenvironment. While others have used 
adhesion phenotyping to differentiate metastatic and non- 
metastatic cells,10 and tropic subpopulations,34 these studies have 
 
successful risk assessments of tropic metastasis require an 
integrated  proteomic  and  genetic approach. 
Our results suggest that tropism depends more upon how 
cells are able to use their integrins to bind to the ECM, rather 
than variations in gene expression, even in genetically similar 
cell lines. We propose that this type of functional screen, across 
many heterogeneous cell lines, and many phenotypes, is inde- 
pendent of these conflicts observed between genetic and pro- 
teomic analyses. This is demonstrated by the fact that the bone, 
brain, and lung tropic phenotypes we obtained were well- 
conserved across cell lines that share the same preferred 
metastatic site, but that have very different integrin gene and 
protein expression (Fig. 2g). As an example, the MDA-MB-231 
and SUM1315  MO2 cells are both bone metastatic in mice,2,37  
and   both   matched   our   bone   fingerprint,   even   though   the 
MDA-MB-231 cell line has significantly higher surface expres- 
sion of a2 and a5 integrins, and lower expression of avb3, than 
the SUM1315 MO2 cell line.56  Others have shown that    meta- 
stasis depends upon activation, rather than simply expression, 
of integrins.57–59 It is known that splicing variation of a single 
integrin can initiate cancer stem cell plasticity and likely 
impact tropism.16 Taken together, this suggests that under- 
standing the true role of integrins in mediating tropism 
requires a functional analysis of how metastatic cells interact 
with the tissue site, as we have taken here, rather than a limited 
view of only gene expression profiles. 
One study took a similar approach to ours and examined 
cancer cell behavior on different biomaterial surfaces, but 
focused on stiffness as the driving force.7 They found that 
measurements of cell area were not predictive  of  metastasis, 
but there was a weak correlation between both migration and 
proliferation with metastatic site preference.7 Upon our own 
closer examination, their data shows that tropic subpopulation 
cell areas were more sensitive to the biomaterial environments 
than the non-tropic subpopulations, consistent with our results 
(Fig. S4a, ESI†). This suggests that applying our approach to 
other microenvironment cues, such as material stiffness, would 
provide further insight into the biophysical regulation of tropism 
and  add another  dimension to the  fingerprint reported here. 
Integrins are attractive therapeutic targets for metastasis 
because they mediate adhesion to the tissue microenvironment, 
can confer resistance to treatments, and drive disease progression 
and stemness.16,60,61 However, integrin-targeted therapeutics have 
experienced limited clinical success,42 and some potentially 
dangerous outcomes have been reported.62,63 Others have 
shown that inhibiting b1 integrin can reduce primary tumor 
growth, but this subsequently promotes lung metastasis by 
switching the migration mode of triple negative 4T1 mouse 
breast cancer cells from collective to single cell migration, 
observed both via knockdown and antibody targeting.63 Similar 
to these results, we saw both efficacious and dangerous cell 
adhesion and motility phenotypes when we targeted integrin 
binding on our ECMs. b1 and a2 integrin antibody treatment on 
ECM 1 prevented spreading, but increased both 2D motility and 
3D invasion of the SkBr3 cell line (Fig. 3c–g). In the highly 
metastatic MDA-MB-231 cell line, our b1, a2, and a6 integrin 
antibodies each reduced adhesion and motility (Fig. 3a and b), 
but also dangerously increased the phenotypic similarity to 
brain tropism (Fig. 4a). These dangerous phenotypes may result 
from plasticity and adaptability of metastatic cells when integ- 
rins are targeted,62,64 which is potentially responsible, in part, 
for the lack of clinical success of integrin  therapeutics. 
These results highlight the  known  heterogeneity  challenge 
in breast cancer, and there is a ground swell toward persona- 
lized therapeutics. As proof of concept toward using our plat- 
form for discovery of treatments for metastasis in this 
heterogeneous disease, we examined cell lines from two clinical 
subtypes with poor prognosis, and found that they displayed 
striking differences in response to integrin antibodies. In our 
fingerprinting results, these cell lines only shared two of nine 
possible    responses    to    the    integrin    antibodies,  suggesting 
subtype-specific roles for b1, a2, and a6 integrins in bone, brain, 
and lung metastasis. The MDA-MB-231 tropism was equally 
affected by each of these integrin antibodies, while the SkBr3 
cell line was much more sensitive to b1 integrin targeting than 
to  targeting  a2  or  a6  integrins.  Supporting  the subtype-specific 
responses we observed, there is in vivo evidence for distinct 
roles of the same integrin in tumorigenesis and metastasis in 
different types of breast cancer.64 In PyV-MT tumors, b1 integrin 
is required for tumor initiation. However, in mice that also 
express active erbB2 (HER2), b1 integrin is only necessary to 
mediate lung metastasis, while  tumorigenesis  is  independent  
of b1 integrin.
64 In our work, b1  integrin targeting had  no effect 
on the MDA-MB-231 lung tropism, but significantly decreased 
lung tropism in the HER2+ SkBr3 cell line. However, of the  
eleven cases where integrin gene expression predicts for tropic 
metastasis in the clinic, only two were conserved for both the 
triple negative and HER2+ patient subpopulations (Fig. 4). This 
indicates that integrins are not conserved biomarkers  across  
the entire heterogeneous patient population, necessitating 
subtype- or even tumor-specific screening to identify successful 
integrin therapeutics. We suggest that this type of functional 
screening  would  be  capable  of  identifying  efficacious    tumor- 
specific therapeutics, providing additional insight in combi- 
nation  with  current  genetics-based approaches. 
Conclusions 
Here, we developed a simple, yet robust in vitro biomaterial 
platform that allowed us to quantify many different cell pheno- 
types associated with adhesion and motility in order to take a 
comprehensive view of how integrin–ECM interactions regulate 
bone, brain, and lung metastasis. Importantly, these results 
would not have been realized by simply looking at individual 
measurements, and required us to instead quantify patterns of 
measurements. This compiled pattern of measurements created 
a phenotypic fingerprint, which is dependent only on integrin 
binding to the ECM, and can predict integrin-mediated meta- 
static spread in cell lines. Our results suggest that targeting 
integrins across the heterogeneous breast cancer clinical sub- 
types is not appropriate (Fig. 3 and 4), potentially explaining  the 
 
lack of success of integrin-targeted therapeutics thus far. Impor- 
tantly, our results are largely independent of integrin gene or 
protein expression, highlighting the need for this type of func- 
tional approach, particularly when comparing among different 
breast cancer subtypes. We emphasize the utility of this bio- 
material platform to screen integrin–ECM interactions rapidly 
and reproducibly, and by collectively quantifying patterns of 
phenotypes en masse, the ability to predict in vivo fate with a 
simple  in vitro approach. 
33% collagen IV, 15% collagen I, 15% fibronectin, and 4% 
tenascin C (all weight%). Rat-tail collagen I and natural mouse 
laminin were purchased from Life Technologies; human tenas- 
cin C, human vitronectin, and human osteopontin from R&D 
Systems (Minneapolis, MN, USA); human collagen IV from 
Neuromics (Edina, MN, USA); and human plasma fibronectin 
from EMD Millipore (Billerica, MA, USA). Coverslips were incu- 
bated with proteins at room temperature for three hours, then 
with  10  mg  cm-2  MA(PEG)24  (Thermo  Scientific,  Rockford,  IL, 
USA) for two hours to block non-specific protein adsorption on 
any remaining surface area. 
An ELISA was used to quantify coupling of collagen III (Fig. 
S1, ESI,† 0, 1, 10 and 50 mg cm-2; Fibrogen, San Francisco, CA,  
USA).  Surfaces  were  blocked  with  10  mg  ml-1  BSA  (Fisher 
Scientific) for 1 hour, reacted with 1 : 200 primary antibody 
(Santa Cruz Biotechnology, Dallas, TX, USA) for 1.5  hours, 
and then 1 : 200 HRP-conjugated secondary antibody (Abcam, 
Cambridge, MA, USA) for 1 hour at room temperature, rinsing 
four times with PBS in between each step. Coverslips were 
incubated with 0.1 M sodium acetate (pH 5.5) containing 1  
mg  ml-1  3,3 0,5,50-tetramethylbenzidine  (Sigma-Aldrich)  and 
0.05 wt% hydrogen peroxide (Fisher Scientific) and the reaction 
proceeded for 30 minutes, then was stopped with 1 M H2SO4 
(Sigma-Aldrich). The absorbance at 450 nm was read immedi- 
ately (Biotech  ELx800,  Winooski,  VT, USA). 
Materials and methods 
Cell culture 
Human breast cancer cell lines MDA-MB-231,  BT549,  MCF7,  
and SkBr3 were generous gifts from Shannon Hughes at the 
Massachusetts Institute of Technology. Highly metastatic MDA- 
MB-231 variants, isolated from in vivo selection, were kindly 
provided  by  Joan  Massague´.2–4  These  cell  lines  preferentially 
metastasize to the bone (1833 BoM), brain (831 BrM2a) or lung 
(4175 LM2). All were routinely cultured in Dulbecco’s Modified 
Eagle’s Medium supplemented with 10% fetal bovine serum 
(FBS), 1% penicillin–streptomycin (P/S), 1% L-glutamine, and 
1% non-essential amino acids. The MDA-MB-361, SUM1315  
MO2, MDA-MB-468, and  HCC  1954  cell  lines  were  provided  
by  Mario   Niepel  at   Harvard  Medical   School.   SUM1315  MO2 
cells were cultured in Ham’s F-12 medium supplemented with 
5  mg  ml-1  insulin,  10  ng  ml-1  EGF,  10  mM  HEPES,  10%  FBS, 
and 1% P/S. MDA-MB-361 cells were cultured in Leibovitz’s L-15 
medium with 20% FBS and 1% P/S. MDA-MB-468 cells   were 
cultured in Leibovitz’s L-15 medium with 10% FBS and 1% P/S. 
HCC 1954 cells were cultured in RPMI medium with 10% FBS 
and  1%  P/S. With the exception  of the MDA-MB-361 and MDA- 
MB-468 cells, which were cultured without supplemental CO2, all 
cell lines were cultured at 37 1C and 5% CO2. All cell culture 
supplies were purchased from Life Technologies (Carlsbad, CA). 
Cell adhesion and polarization 
Cells  were  seeded  at  4000  cells  per  cm2  in  growth   medium, 
ml-1 medium   supplemented   with   40  ng epidermal  growth 
factor (EGF, R&D Systems) immediately, or with antibody pre- 
treatment, which occurred for 30 minutes prior to seeding. Anti-
b1    integrin   (clone   P5D2,   R&D   Systems)   was   used    at 
0.83  mg  ml-1,  and  anti-a2  and  anti-a6  integrins  were  used  at 
3.3  mg  ml-1  (a2:  clone  P5E6,  a6:  clone  NK1-GoH3,  both  from 
Millipore). Cell adhesion was captured through imaging cells 
beginning 10 minutes after seeding in an environment- 
controlled Zeiss Axio Observer Z1 microscope (Carl Zeiss, 
Oberkochen,   Germany)  using  an   AxioCam  MRm  camera   and Preparation of ECMs 
Glass coverslips (15 mm and 18 mm diameter, Fisher Scientific, 
Agawam, MA, USA) were oxygen plasma treated (Harrick  
Plasma,  Ithaca,  NY,  USA),  and  silanized  through  vapor   phase 
deposition of  (3-aminopropyl)triethoxysilane  (Sigma-Aldrich, 
St. Louis, MO, USA) at  90  1C  for  a  minimum  of  18  hours.65  
The coverslips were rinsed sequentially in toluene (Fisher 
Scientific), 95% ethanol (Pharmco-AAPER,  Brookfield,  CT,  
USA), and water, and dried at 90 1C for one hour. They were 
then functionalized with 10 g L-1 N,N-disuccinimidyl carbonate 
(Sigma-Aldrich) and 5% v/v diisopropylethylamine (Sigma- 
Aldrich) in acetone (Fisher Scientific) for two hours.66 Cover- 
slips were rinsed three times in acetone and air-dried. ECM 
protein cocktails were then covalently bound to the glass 
coverslips through reactive amines,67 using cocktails that were 
inspired by the ECM of secondary sites as follows: ECM 1 (bone): 
5 mg cm-2 of 99% collagen I and 1% osteopontin; ECM 2 (brain): 
1 mg cm-2 of 50% fibronectin, 25% vitronectin, 20% tenascin C, 
and 5% laminin; and ECM 3 (lung): 2 mg cm-2 of 33% laminin, 
an  EC  Plan-Neofluar  20x  0.4  NA  air  objective.  Images     were 
taken using AxioVision (Carl Zeiss) at five-minute intervals for a 
minimum of 2 hours until cells  had  reached  steady-state. 
ImageJ  (National  Institutes  of  Health,  Bethesda,  MD,  USA) 
was used to trace cell areas using the built-in measurement 
function. Spreading rate was defined as the slope of the linear 
portion of the area versus time graph during initial adhesion. 
Individual cells were marked when they had polarized, and the 
fraction of cells that had polarized at 2 hours post-seeding was 
quantified  for  comparison   across  conditions.  Cells  that     con- 
tacted other cells, underwent division or apoptosis, or were not 
fully in frame were excluded. N Z 2 independent biological 
replicates, N Z 40 cells per condition. 
 
Cell migration 
Cells were seeded at 4000 cells per cm2 and given 18 hours to 
adhere in growth medium. Seeded cells were treated with a live- 
cell   fluorescent   dye   (CMFDA,   Life   Technologies),   and   then 
 
provided fresh medium or medium supplemented with EGF 
and/or integrin antibodies (as described above) 4 hours prior to 
microscopy.  Brightfield  and  fluorescent   images   were   taken 
at 15 minute intervals for 12 hours using an EC Plan-Neofluar 
similarity in the appropriate null distribution. Because our 
distributions were comprised of 10 000 cells with only 13 or 
15 possible discrete values, each percentile for a cell line had a 
range, illustrated via the error bars in Fig. 2g. Cell lines in the 
top or bottom 5% of the ordered distributions were considered 
to be significantly higher or lower than the null distribution. 
Specifically, the lowest and highest 500 randomly generated 
cells had p r 0.05. 
Collagen gel invasion 
Cells were seeded at 600 cells per cm2 in normal growth medium 
and  given  12  hours  to  adhere.  Collagen  gels  (2  mg  ml-1)  were 
made by mixing 5% v/v 1 M NaOH (Fisher Scientific), growth 
medium and type I collagen (Life Technologies) on ice. The 
medium was removed from the seeded coverslips, and gel 
solutions were overlaid onto the cells. Gelation proceeded for 
30 minutes at 37 1C and 5% CO2, then 250 ml growth medium 
was added to each well. EGF and integrin antibodies were 
included in the gel solution and the supernatant medium as 
described above. For accurate comparisons, an equal number 
of randomly selected positions were observed in all conditions. 
N = 2 independent biological replicates, each with three techni- 
cal replicates, and 25 positions were imaged per technical 
replicate. 
10x 0.3  NA air  objective  (Carl  Zeiss).  Cells  were  tracked using 
Imaris (Bitplane, St. Paul, MN, USA) to generate individual cell 
paths. Individual cell speeds were determined by calculating a 
speed at every 15 minute time interval, then averaging these 
over the entire 12 hours. Displacement was defined as the net 
change in position of the cell over the total time. Chemotactic 
index is the ratio of a cell’s net displacement to path length. 
Individual cell average speeds, net displacements, and chemo- 
tactic indices were then averaged to determine a mean popula- 
tion value. Cells that contacted other cells, underwent division 
or apoptosis, or were not fully in frame for the entire 12 hours 
were excluded. N Z 2 independent biological replicates, N Z 90 
cells per condition. 
Fingerprinting 
We  quantified  adhesion and   migration   phenotypes   for  the 
three tropic subpopulations, both under normal and EGF- 
stimulated conditions. To create phenotypic fingerprints, first, 
we calculated the CoV (standard deviation divided by average, 
calculated for final mean values for one  measurement  across 
the three ECMs) for each tropic cell line to determine their ECM-
sensitivity in each parameter (a CoV greater than 0.1 was 
considered ECM-sensitive; Fig. 2a and d). Second, we  quanti- 
fied the fold-change in these metrics in response to EGF 
stimulation on each ECM (fold-changes greater than  1.15  or  
less than 0.85 were defined as significant; Fig.  2b  and  e).  
Finally, we did all pairwise statistical comparisons across ECMs 
(via a one-way ANOVA, described below), and quantified order- 
ing of values (i.e., for normal speed measurements, was ECM 1 
greater than, equal to, or less than ECM 2; Fig. 2c and Fig. S4b, 
ESI†). We then compiled this data to create a fingerprint of the 
66 phenotypes associated with a specific tissue preference 
(Fig. 4d and e and Fig. S4b, ESI†). Upon comparison of each 
phenotype across the three tropic subpopulations, only those 
phenotypes which were identified in just one tropic cell line 
were retained, and all phenotypes shared in two or three of the 
cell lines were ignored (Fig. 4b–e, and Fig. S4b, ESI,† dark 
colors). To validate these fingerprints, we calculated these same 
criteria for other cell lines with  known  in  vivo  metastasis. 
We  then  overlaid  these  patterns  onto  each  tropic fingerprint, 
Gene expression analysis 
Gene expression data from primary breast tumors (GSE 2034, 
GSE 2603, GSE 5327, and GSE 12276) was retrieved from the 
NCBI Gene Expression Omnibus (GEO)  database.  Each  was 
RMA normalized using the R platform (Vienna, Austria).68 
Datasets were  cross-mapped  based  upon  common  probes, 
and batch effects were corrected with an Empirical Bayes 
method using the ComBat algorithm in R.69  Genes represented 
by more than one probe were collapsed to the probe with the 
highest mean value. For metastasis-free survival analysis, 
patients with known metastasis and clinical subtype informa- 
tion were classified into groups of high and low gene expres- 
sion based upon median expression. Published survival and 
clinical subtype information was used.4,51 Survival was analyzed 
in Prism v6.0b (GraphPad Software, La Jolla, CA, USA), and 
significance was evaluated using a log-rank (Mantel–Cox) test. 
To analyze integrin expression in the tropic cell lines, GSE 2603 
and GSE 12237 were retrieved from the NCBI GEO database, 
RMA normalized, combined using the ComBat algo- rithm as 
previously described, and data corresponding to the cell 
subpopulations used here (1833, BrM2a, and 4175) were 
extracted. Individual integrin genes were extracted, values were 
collapsed to the probe with the highest expression, and a heat 
map  was  generated  in R. 
and   quantified   the  fractional   similarity   between   each   cell line 
and the unique phenotypes within these fingerprints (Fig. 2g and 
Fig. S5a, ESI†). 
Null distributions of bone, brain, and lung tropisms were 
generated via a custom code written in MATLAB R2012a (The 
MathWorks, Inc., Natick, MA). 10 000 random cell line pheno- 
types were generated and were compared with the unique 
features of the bone, brain, and lung fingerprints to obtain 
tropism similarity values. The distributions were ordered, 
percentiles assigned, and then the heterogeneous  cell  lines  
were compared with each of these null distributions, matching 
their  similarity  with  the  percentile  associated  with  this  same 
Reverse-transcriptase PCR 
Cells were seeded at 40 000 cells per cm2 and allowed to adhere 
to coverslips or tissue culture plastic for a minimum of 18 hours. 
Coverslips or wells were washed with PBS prior to detaching cells 
with 0.05% trypsin–EDTA (Life Technologies). Total RNA was 
extracted using the Genelute Mammalian Total RNA kit    (Sigma) 
 
followed by cDNA synthesis using the RevertAid reverse tran- 
scriptase protocol, with the exception of using RNasin 40 U mL-1, 
(Promega, Madison, WI) as the RNase inhibitor. The amplifica- 
tion was carried out with Jumpstart Taq polymerase according to 
the manufacturer’s instructions using a BioRad MJ Mini Perso- 
nal thermal cycler (Hercules, CA). Primer sequences (Integrated 
DNA Technology, Coralville, IA) were as follows: 
GAPDH (NM_001256799.1) forward 50-CACTGACACGTTGGC 
AGTGG-30 
reverse 50-CATGGAGAAGGCTGGGGCTC-3 0 
Integrin    b1:    (NM_002211.3)    forward    50-CTGGGCTTTAC 
GGAGGAAGT-30 
reverse 50-GTCTACCAACACGCCCTTCA-30 
Integrin    a2:    (NM_002203.3)    forward    50-CTGGTGTTAGC 
GCTCAGTCA-30 
reverse 50-CCAGGGTGAACCAACCAGTA-30 
Integrin  a6:  (NM_001079818.1)  forward  50-CGAGGACAAGC 
GGCTGTT-30 
reverse 50-TGACCCCCATCCACTGATCT-30 
EGFR: (NM_005228.3) forward 50-CTTCGGGGAGCAGCGATG-30 
reverse 50-CAGCTCCTTCAGTCCGGTTT-30 
Each reaction was analyzed on a 1% agarose gel with 
ethidium bromide staining, then visualized under ultraviolet 
light using the IN Genius Syngene Bioimaging platform 
(Frederick, MD). GAPDH was used as a housekeeping gene. 
N Z 2 independent biological replicates. 
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